Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of ...

Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Predicting weight loss using self-reported, digitally collected, real-world data after initiation of ...